医学检验与临床
醫學檢驗與臨床
의학검험여림상
MEDICAL LATORATORY SCIENCE AND CLINICES
2014年
3期
9-14
,共6页
肺癌%肿瘤标志物%癌胚抗原%胃泌素释放肽前体%鳞状细胞上皮癌抗原%小细胞肺癌
肺癌%腫瘤標誌物%癌胚抗原%胃泌素釋放肽前體%鱗狀細胞上皮癌抗原%小細胞肺癌
폐암%종류표지물%암배항원%위비소석방태전체%린상세포상피암항원%소세포폐암
Lung cancer%Tumor marker%Carcinoembryonic antigen%Pro-astrin releasing peptide%Squamous cell carcinoma antigen%Small cell lung cancer
目的：肺癌是世界范围内发病率和死亡率最高的恶性肿瘤。肿瘤标志物已经成为人们探究如何早期诊断肺癌的主题之一。单项肿瘤标志物检测对肺癌的诊断存在不同程度的局限性，因此需探讨针对肺癌早期诊断更具有临床意义的综合诊断方法。本研究通过回顾我院2012-2013四种肺癌肿瘤标志物在肺部疾病住院患者及健康查体者血清中的表达水平，分析并探讨在肺癌早期诊断中血清肿瘤标志物CEA,CYFRA21-1,SCC,ProGRP联合检测的价值。方法：研究对象为2012-2013年间我院有全套肿瘤标志物记录的肺部疾病住院患者和健康查体者。原发性肺癌者均经病理学或细胞学证实并分型，共163例（鳞癌63例，腺癌66例，小细胞癌34例）。肺良性疾病组70例，排除标准：同时合并有其它恶性肿瘤者。健康查体者为对照组，均非患有肺部疾病和肿瘤性疾病，共85例。各组间性别、年龄均无统计学差异。经化学发光免疫法测定所有研究对象的血清标本，使用仪器为雅培I2000SR全自动化学发光免疫分析仪。统计学采用SPSS 17.0软件，计量资料以均数±标准差表示，计量资料采用方差分析及多重比较，α采用0.05水平，多重比较调整α为0.025水平。结果：肺癌组血清CEA、CYFRA21-1、SCC、ProGRP水平高于肺良性疾病组，同时高于对照组。在小细胞癌组中，患者ProGRP水平高于其血中CEA、Cyfra21-1及SCC的水平。腺癌患者血CEA水平较鳞癌及小细胞癌患者为高。在鳞癌患者中CYFRA21-1以及SCC水平高于腺癌、小细胞癌患者。CEA单独检测灵敏度较高，特异度较低。上述四项指标联合检测，对肺癌的早期诊断的灵敏度与特异度均有不同的提高。差异均具有显著统计学意义（P<0.05）。结论：1.肺癌组患者血清肿瘤标志物水平显著高于肺良性疾病组，肺良性疾病组血显著高于对照组。2.ProGRP 对小细胞肺癌的敏感性高于另外三项肿瘤标志物。3.CEA 对腺癌的敏感性高于鳞癌、小细胞肺癌和其他细胞类型。4.以上四种肿瘤标志物联合检测可以明显提高肺癌早期诊断的正确率。
目的：肺癌是世界範圍內髮病率和死亡率最高的噁性腫瘤。腫瘤標誌物已經成為人們探究如何早期診斷肺癌的主題之一。單項腫瘤標誌物檢測對肺癌的診斷存在不同程度的跼限性，因此需探討針對肺癌早期診斷更具有臨床意義的綜閤診斷方法。本研究通過迴顧我院2012-2013四種肺癌腫瘤標誌物在肺部疾病住院患者及健康查體者血清中的錶達水平，分析併探討在肺癌早期診斷中血清腫瘤標誌物CEA,CYFRA21-1,SCC,ProGRP聯閤檢測的價值。方法：研究對象為2012-2013年間我院有全套腫瘤標誌物記錄的肺部疾病住院患者和健康查體者。原髮性肺癌者均經病理學或細胞學證實併分型，共163例（鱗癌63例，腺癌66例，小細胞癌34例）。肺良性疾病組70例，排除標準：同時閤併有其它噁性腫瘤者。健康查體者為對照組，均非患有肺部疾病和腫瘤性疾病，共85例。各組間性彆、年齡均無統計學差異。經化學髮光免疫法測定所有研究對象的血清標本，使用儀器為雅培I2000SR全自動化學髮光免疫分析儀。統計學採用SPSS 17.0軟件，計量資料以均數±標準差錶示，計量資料採用方差分析及多重比較，α採用0.05水平，多重比較調整α為0.025水平。結果：肺癌組血清CEA、CYFRA21-1、SCC、ProGRP水平高于肺良性疾病組，同時高于對照組。在小細胞癌組中，患者ProGRP水平高于其血中CEA、Cyfra21-1及SCC的水平。腺癌患者血CEA水平較鱗癌及小細胞癌患者為高。在鱗癌患者中CYFRA21-1以及SCC水平高于腺癌、小細胞癌患者。CEA單獨檢測靈敏度較高，特異度較低。上述四項指標聯閤檢測，對肺癌的早期診斷的靈敏度與特異度均有不同的提高。差異均具有顯著統計學意義（P<0.05）。結論：1.肺癌組患者血清腫瘤標誌物水平顯著高于肺良性疾病組，肺良性疾病組血顯著高于對照組。2.ProGRP 對小細胞肺癌的敏感性高于另外三項腫瘤標誌物。3.CEA 對腺癌的敏感性高于鱗癌、小細胞肺癌和其他細胞類型。4.以上四種腫瘤標誌物聯閤檢測可以明顯提高肺癌早期診斷的正確率。
목적：폐암시세계범위내발병솔화사망솔최고적악성종류。종류표지물이경성위인문탐구여하조기진단폐암적주제지일。단항종류표지물검측대폐암적진단존재불동정도적국한성，인차수탐토침대폐암조기진단경구유림상의의적종합진단방법。본연구통과회고아원2012-2013사충폐암종류표지물재폐부질병주원환자급건강사체자혈청중적표체수평，분석병탐토재폐암조기진단중혈청종류표지물CEA,CYFRA21-1,SCC,ProGRP연합검측적개치。방법：연구대상위2012-2013년간아원유전투종류표지물기록적폐부질병주원환자화건강사체자。원발성폐암자균경병이학혹세포학증실병분형，공163례（린암63례，선암66례，소세포암34례）。폐량성질병조70례，배제표준：동시합병유기타악성종류자。건강사체자위대조조，균비환유폐부질병화종류성질병，공85례。각조간성별、년령균무통계학차이。경화학발광면역법측정소유연구대상적혈청표본，사용의기위아배I2000SR전자동화학발광면역분석의。통계학채용SPSS 17.0연건，계량자료이균수±표준차표시，계량자료채용방차분석급다중비교，α채용0.05수평，다중비교조정α위0.025수평。결과：폐암조혈청CEA、CYFRA21-1、SCC、ProGRP수평고우폐량성질병조，동시고우대조조。재소세포암조중，환자ProGRP수평고우기혈중CEA、Cyfra21-1급SCC적수평。선암환자혈CEA수평교린암급소세포암환자위고。재린암환자중CYFRA21-1이급SCC수평고우선암、소세포암환자。CEA단독검측령민도교고，특이도교저。상술사항지표연합검측，대폐암적조기진단적령민도여특이도균유불동적제고。차이균구유현저통계학의의（P<0.05）。결론：1.폐암조환자혈청종류표지물수평현저고우폐량성질병조，폐량성질병조혈현저고우대조조。2.ProGRP 대소세포폐암적민감성고우령외삼항종류표지물。3.CEA 대선암적민감성고우린암、소세포폐암화기타세포류형。4.이상사충종류표지물연합검측가이명현제고폐암조기진단적정학솔。
Objective:Lung cancer is the highest incidence and mortality rates of malignant tumors all over the world. Tumor markers have become a hot research in early diagnosis of lung cancer. Single tumor marker detection only has high sensitivity to specific types of lung cancer; combined detection of tumor markers has more clinical significance for the diagnosis of lung cancer. Therefore, by retrospective studying the levles of tumor markers in lung cancer of the patients with lung diseases and check body inpatients in our hospital between 2012 and 2013, the study analysis, discusses and clears the value of serum tumor markers CEA, CYFRA21-1, SCC and ProGRP in diagnosis of lung cancer.Methods:The objects of study are checking body inpatients and healthy full set of tumor marker detection records of lung disease in our hospital between 2012 and 2013. The number of Primary lung cancers who were confirmed by pathology or cytology and classified is 163, including 63 cases of squalors cell carcinoma, 66 cases of adenocarcinoma and 34 cases of small cell carcinoma. Benign lung disease group has 70 patients, exclusion criteria: associated with other parts of tumor. The group of Healthy subjects who were not suffering from lung disease and neoplastic diseases is control group, which has 85 cases. There were no significant differences between groups of gender, age. The serological detection of all retrospective studying subjects is determinated by Abbott I2000SR automated chemiluminescence immunoassay analyzer by chemiluminescent immunoassay.Using SPSS 17.0 statistical software, measurement data as mean ± standard deviation, variance analysis and measurement data using multiple comparisons, α level of 0.05, adjusted for multiple comparisons α 0.025 level.Results:the level of CEA, CYFRA21-1, SCC, and ProGRP in lung cancer serum group is higher than that of benign pulmonary disease group, and also higher than that of control group. In the small cell carcinoma group, the level of ProGRP is higher than that of CEA, CYFRA21-1, and SCC l. The level of CEA in Adenocarcinoma is higher than that of squamous cell carcinoma and small cell carcinoma. The levels of SCC and CYFRA21-1 in squamous cell carcinoma are higher than that in adenocarcinoma and small cell carcinoma. CEA alone has higher detection sensitivity, specificity is low. The combined detection of the four indexes, the sensitivity and specificity were improved. These differences had statistically significant (P<0.05).Conclusions:1. The serum tumor markers in patients with lung cancer group was significantly higher than that in benign pulmonary disease group,, the serum tumor markers in lung benign disease group were significantly higher than those in the control group. 2. The sensitivity of ProGRP in small cell lung cancer was higher than that of other tumor markers. 3. The sensitivity of CEA in adenocarcinoma is higher than that in squamous cell carcinoma, small cell lung cancer and other cell types. 4 tumor markers can improve the correct rate of diagnosis of lung cancer.
